(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. \u0010 \u0010GUEST: \u0010Cynthia Koons \u0010Health Care Reporter \u0010Bloomberg Editorial \u0010on Pfizer beating out rivals to buy biopharmaceutical company, Medivation, and its blockbuster cancer drug for $14 billion.
 Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. \u0010 \u0010GUEST: \u0010Cynthia Koons \u0010Health Care Reporter \u0010Bloomberg Editorial \u0010on Pfizer beating out rivals to buy biopharmaceutical company, Medivation, and its blockbuster cancer drug for $14 billion. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Koons on Pfizer Agreeing to Buy Medivation (Audio)

Matt Miller and Paul Sweeney focus on market coverage as Wall Street begins its day, with analysis from Bloomberg Opinion writers, Bloomberg Intelligence analysts, and influential newsmakers.

Share Koons on Pfizer Agreeing to Buy Medivation (Audio)

Sign up to save your podcasts

Koons on Pfizer Agreeing to Buy Medivation (Audio)

Koons on Pfizer Agreeing to Buy Medivation (Audio)